Insider Buying: The Oncology Institute, Inc. (NASDAQ:TOI) Director Acquires 250,000 Shares of Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Brad Hively bought 250,000 shares of Oncology Institute stock in a transaction dated Tuesday, November 26th. The stock was acquired at an average price of $0.17 per share, for a total transaction of $42,500.00. Following the completion of the acquisition, the director now owns 616,753 shares in the company, valued at approximately $104,848.01. The trade was a 68.17 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Brad Hively also recently made the following trade(s):

• On Monday, December 2nd, Brad Hively purchased 50,000 shares of Oncology Institute stock. The stock was bought at an average price of $0.15 per share, with a total value of $7,500.00.

Oncology Institute Trading Down 4.0 %

Shares of NASDAQ:TOI traded down $0.01 during trading on Monday, hitting $0.16. The company had a trading volume of 1,904,948 shares, compared to its average volume of 422,813. The stock has a market cap of $11.75 million, a price-to-earnings ratio of -0.20 and a beta of 0.60. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The company has a fifty day simple moving average of $0.28 and a two-hundred day simple moving average of $0.39. The Oncology Institute, Inc. has a one year low of $0.13 and a one year high of $2.50.

Institutional Trading of Oncology Institute

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Tiff Advisory Services LLC grew its holdings in Oncology Institute by 235.1% during the 2nd quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock valued at $653,000 after purchasing an additional 995,280 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Oncology Institute by 142.3% during the second quarter. Renaissance Technologies LLC now owns 339,400 shares of the company’s stock valued at $156,000 after buying an additional 199,300 shares during the last quarter. Finally, HighTower Advisors LLC raised its holdings in shares of Oncology Institute by 190.8% in the third quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after buying an additional 53,382 shares during the period. Hedge funds and other institutional investors own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.